RVNC | Revance Therapeutics Inc
Category: Consumer goods
Quick infos Headquarters: Newark, California, United States Trade prices Volume: Market Cap: 1.04B Prev closed: Open: High: Low: 52 week low: 52 week high: Dividends: No Dividends Next ER: February 28, 2023 After Market Closes
Earnings History Date EPS / Forecast Revenue / Forecast May 9, 2023 February 28, 2023 -1.82 / -0.7449.9M / 44.91MBeat! November 8, 2022 -0.8456 / -0.789829.02M / 28.24MBeat! August 9, 2022 -0.67 / -0.762528.37M / 28.15MBeat! May 10, 2022 -0.6511 / -0.797125.26M / 23.76MBeat! view more
Historical Data Date Price Open High Low Vol Change ER Aug 9, 2022 17.47 19.01 19.45
16.47
1.46M -9.67% Aug 8, 2022 19.34 19.73 20.20
19.28
655.00K -1.58% Aug 5, 2022 19.65 17.99 19.69
17.95
691.63K 7.38% Aug 4, 2022 18.30 18.03 18.52
17.84
403.12K 1.67% Aug 3, 2022 18.00 17.04 18.01
17.04
686.16K 7.14% Aug 2, 2022 16.80 15.52 16.85
15.39
999.71K 7.28% Aug 1, 2022 15.66 15.59 16.12
15.31
595.09K 0.90% Jul 29, 2022 15.52 15.68 15.68
14.51
1.13M -1.08% Jul 28, 2022 15.69 15.92 15.92
15.28
258.86K -0.88% Jul 27, 2022 15.83 15.81 16.00
15.39
274.04K 0.64% view more
RVNC
More profiles and info about the company News
Revance surges 45% as it sees revenue from RHA collection to be between $34M and $35M seekingalpha.com Jan 9, 2023 11:36 pm
Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results finance.yahoo.com Jan 9, 2023 8:00 am
Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 finance.yahoo.com Nov 23, 2022 8:00 am
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference finance.yahoo.com Nov 22, 2022 8:00 am
Revance Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags finance.yahoo.com Nov 10, 2022 5:32 am Revance Therapeutics GAAP EPS of -$1.17 misses by $0.23, revenue of $29M beats by $0.76M seekingalpha.com Nov 9, 2022 5:34 am Revance Therapeutics Q3 2022 Earnings Preview seekingalpha.com Nov 8, 2022 6:35 am Revance Therapeutics submits sBLA for Daxxify for cervical dystonia seekingalpha.com Oct 20, 2022 11:19 pm
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Tops Revenue Estimates finance.yahoo.com Nov 8, 2022 6:05 pm
Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment finance.yahoo.com Nov 4, 2022 8:00 am
Heres What Makes Revance Therapeutics (RVNC) an Attractive Investment finance.yahoo.com Nov 1, 2022 1:01 pm
Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia finance.yahoo.com Oct 20, 2022 8:00 am Revance appoints David Hollander, M.D as CMO seekingalpha.com Oct 17, 2022 8:18 pm
Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting finance.yahoo.com Oct 10, 2022 8:00 am
Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal finance.yahoo.com Sep 19, 2022 8:00 am
Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS) finance.yahoo.com Sep 15, 2022 4:06 pm
RVNC NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit finance.yahoo.com Sep 13, 2022 8:05 pm
REVANCE THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC finance.yahoo.com Sep 13, 2022 7:01 pm
Revance Therapeutics Class Action Reminder finance.yahoo.com Sep 13, 2022 6:58 pm
Revance Therapeutics Shareholder Alert finance.yahoo.com Sep 13, 2022 6:45 pm This company doesn't provide a dividend.
Talk about Revance Therapeutics Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus BUY 86 HOLD 14 SELL 0
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.